跳至主要内容
临床试验/NCT05730634
NCT05730634已完成不适用

The Effect of Statin Treatment on Arterial Wall Inflammation in Patients With Diabetes Mellitus as Assessed With 68Ga-DOTATATE PET-CT

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2019年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
1
主要终点
DOTATATE coronary arteries

研究概览

简要总结

To study the effect of atorvastatin treatment on vascular uptake of 68Ga-DOTATATE in patients with Type 2 Diabetes.

详细描述

Well controlled patients with type 2 diabetes, who are statin naïve, will undergo atorvastatin treatment. Before and after treatment, patients will undergo a 68Ga-DOTATATE PET/CT, to evaluate the effect of treatment on vascular inflammation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 50 years and older
  • Diagnosed with diabetes mellitus type 2 and using oral glucose lowering therapy, insulin or combined glucose lowering therapy.
  • Not on statin therapy or willing to stop with current statin therapy for 6 weeks prior to visit
  • HbA1c values below 65 mmol/L.
  • Patients with "stable" diabetes mellitus, i.e. no changes in type of glucose lowering therapy and / or dosage of oral glucose lowering therapy in the past three months. No more than 20% change in dosage of insulin therapy (short and long acting) in the last three months.

排除标准

  • History of cardiovascular disease (previous CV-event (MI / stroke) or known coronary artery disease (including acute coronary syndrome).
  • History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of < 45 ml/min/1,73m2
  • Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
  • Chronic or recent (< 1 month) infections and/or clinical signs of acute infection.
  • History of auto-immune diseases.
  • Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices.
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
  • Planned radiation exposure in the next year due to participation in a research project with radiation exposure or for clinical reasons.
  • Elevated liver enzymes (> 2 ULN of liver transaminases), acute liver failure or known liver disease.
  • Prior medium to severe statin-related side effects or statin related hypersensitivity, i.e.
  • (severe) muscle pains with and/or without myopathy .
  • The concomitant use of statin contra-indicated drugs, including the use of CYP3A4 inhibitors (i.e. erytromycin, dilthiazem, amiodaron, verapamil, fluconazole, ciclosporin, stiripentol, itraconazol, ketoconazol, voriconazol, posaconazol, clarithromycin, ..), systemic use of fusidic acid and ciclosporin.
  • Any contra-indications to the use of statins.

研究组 & 干预措施

Intervention arm

Experimental

Atorvastatin 40mg once daily.

干预措施: Atorvastatin 40 Mg Oral Tablet (Drug)

结局指标

主要结局

DOTATATE coronary arteries

时间窗: 3 months

Change in DOTATATE TBRmax coronary arteries after atorvastatin therapy

次要结局

  • Change in splenic/bone marrow DOTATATE signal(3 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nordin Hanssen

Dr.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

研究点 (1)

Loading locations...

相似试验

The Effect of Statin Treatment on Arterial Wall... | 临床试验